uniQure (NASDAQ:QURE) Price Target Raised to $31.00 at Chardan Capital

uniQure (NASDAQ:QURE) had its target price increased by Chardan Capital from $16.00 to $31.00 in a research note issued to investors on Monday morning, MarketBeat reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also issued reports on the company. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $15.00 to $60.00 in a research report on Monday. Wolfe Research started coverage on uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of uniQure in a research note on Tuesday, February 10th. William Blair reiterated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Finally, Barclays started coverage on shares of uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, uniQure presently has an average rating of “Hold” and a consensus target price of $41.33.

uniQure Price Performance

QURE stock opened at $17.99 on Monday. The stock has a 50-day moving average price of $21.90 and a two-hundred day moving average price of $29.64. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The stock has a market cap of $1.12 billion, a PE ratio of -5.21 and a beta of 0.73. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. Equities analysts forecast that uniQure will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the transaction, the chief financial officer owned 226,581 shares of the company’s stock, valued at $2,052,823.86. The trade was a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 81,399 shares of company stock worth $1,527,645. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Several institutional investors and hedge funds have recently bought and sold shares of the business. Private Trust Co. NA acquired a new stake in shares of uniQure in the third quarter valued at approximately $28,000. Jones Financial Companies Lllp increased its holdings in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 5.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares during the last quarter. Arizona State Retirement System raised its stake in uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 627 shares during the period. Finally, Ensign Peak Advisors Inc raised its stake in uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 650 shares during the period. Institutional investors own 78.83% of the company’s stock.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Analyst upgrades and price‑target increases lifting sentiment — Wells Fargo upgraded QURE to “overweight” with a $60 PT and Chardan boosted its PT to $31 with a buy rating; RBC moved to “outperform” with a $35 PT. These calls drove constructive re‑ratings and buy-side interest. Wells Fargo Upgrade Chardan PT Raise
• Positive Sentiment: Regulatory leadership change in the FDA (CBER director Vinay Prasad’s announced exit) is being interpreted by the market as easing near‑term regulatory risk for gene‑therapy programs, prompting a sector rally that lifted uniQure shares. Blockonomi: Stock Soars on FDA Exit Benzinga: Biotech Reaction
• Neutral Sentiment: Analyst and media coverage is spotlighting uniQure ahead of key AMT‑130 catalysts; these pieces increase visibility but do not change fundamentals absent clinical or regulatory news. 24/7 Wall St. Analyst Interest
• Negative Sentiment: Multiple law firms have filed or publicized investor notices seeking lead plaintiffs for a securities class action covering Sept. 24–Oct. 31, 2025 (claims tied to AMT‑130 disclosures). The proliferation of filings (Faruqi, Hagens Berman, Levi & Korsinsky, Portnoy, Rosen) creates legal and disclosure risk and could impose costs or settlement pressure. Faruqi & Faruqi Notice Hagens Berman Alert Levi & Korsinsky Notice Portnoy Law Firm Rosen Law Firm Notice
• Negative Sentiment: Coverage highlighting “confusion” and shifting narratives around uniQure’s disputes with the FDA over AMT‑130 suggests ongoing regulatory uncertainty that could weigh on valuation until resolved. The Pharma Letter: Confusion Grows Yahoo Finance: Shifting Narrative

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.